Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

Human Gene Therapy Clinical Development

Volumn 27, Issue 2, 2016, Pages 69-78

  Patel, Daxa M ^a   Foreman, Paul M ^a   Nabors, L Burt ^a   Riley, Kristen O ^a   Gillespie, G Yancey ^a   Markert, James M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G 207; INTERLEUKIN 12; M 032; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CELL DEATH; CLINICAL PROTOCOL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION STUDY; GLIOBLASTOMA; GLIOSARCOMA; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; STEREOTACTIC BIOPSY; STUDY DESIGN; TUMOR GROWTH; TUMOR VOLUME; VIRUS REACTIVATION; VIRUS SHEDDING; ADMINISTRATION AND DOSAGE; ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; MAXIMUM TOLERATED DOSE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR RECURRENCE; VIRUS REPLICATION;

ASTROCYTOMA; BRAIN NEOPLASMS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; GLIOSARCOMA; HERPESVIRUS 1, HUMAN; HUMANS; INTERLEUKIN-12; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROGNOSIS; PROSPECTIVE STUDIES; RESEARCH DESIGN; VIRUS REPLICATION;

EID: 84991520020     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2016.031     Document Type: Article

References (29)

1. ClinicalTrials. gov. Genetically Engineered HSV-1 Phase 1 Study (M032-HSV-1). U. S. National Institutes of Health, 2014.
2. Andreansky SS, He B, Gillespie GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A 1996;93: 11313-11318.
3. Levine A. Principles and Practice of Oncology. (Lippincott Williams and Wilkins, New York). 1989.
4. Parker JN, Bauer DF, Cody JJ, et al. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 2009;6:558-569.
5. Friedman GK, Pressey JG, Reddy AT, et al. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 2009;17:1125-1135.
6. Markert JM, Parker JN, Buchsbaum DJ, et al. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006;13:66-71.
7. Shah AC, Benos D, Gillespie GY, et al. Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003;65:203-226.
8. Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134. 5, a gene nonessential for growth in culture. Science 1990;250:1262-1266.
9. Chou J, Roizman B. The gamma 1(34. 5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A 1992;89: 3266-3270.
10. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000;7: 867-874.
11. Hellums EK, Markert JM, Parker JN, et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 2005;7: 213-224.
12. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000;97:2208-2213.
13. Parker JN, Meleth S, Hughes KB, et al. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 2005;12:359-368.
14. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996;93:11302-11306.
15. Chua AO, Chizzonite R, Desai BB, et al. Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994; 153:128-136.
16. Toda M, Martuza RL, Kojima H, et al. In situ cancer vaccination: An IL-12 defective vector/ replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998;160:4457-4464.
17. Bramson JL, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7:1995-2002.
18. Wu CY, Demeure C, Kiniwa M, et al. IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J Immunol 1993;151:1938-1949.
19. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147: 874-882.
20. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177: 1199-1204.
21. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-586.
22. Asselin-Paturel C, Lassau N, Guinebretiere JM, et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 1999;6: 606-615.
23. Kikuchi T, Joki T, Akasaki Y, et al. Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells. Cancer Lett 1999;135:47-51.
24. Mikami T, Kurisu K, Kiya K, et al. Antitumor effect of recombinant human lymphotoxin on a tumor line of human malignant glioma. Hiroshima J Med Sci 1989;38:103-107.
25. Markert JM, Cody JJ, Parker JN, et al. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol 2012;86:5304-5313.
26. Roth JC, Cassady KA, Cody JJ, et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 2014;25:16-27.
27. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009;17:199-207.
28. Markert JM, Razdan SN, Kuo HC, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 2014;22:1048-1055.
29. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937.